Yahoo Finance

Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after ...

Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with a PD diagnosis over 3 years compared to baseline and placebo MALVERN, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- via IBN ...
Nasdaq

MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease

Significant improvement of 18 points in Unified Parkinson’s Disease Rating Scale (UPDRS) Part 3 in the high dose group at 26 weeks Significant improvement in the Parkinson’s Disease Questionnaire (PDQ ...
Hosted on MSN

Bayer’s cell therapy shows 3-year improvement in Phase I Parkinson’s trial

Bayer-owned BlueRock Therapeutics’ cell therapy hopeful has shown clinically meaningful improvements 36 months in an early-phase Parkinson’s disease study. Bemdaneprocel improved MDS-unified Parkinson ...
Nasdaq

Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after ...

Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a very ...